Newsletters

Psychiatry Advisor

• What Is the Optimal Dose of Ketamine for Treatment Resistant Depression? April 30, 2024
  Investigators conducted a systematic review and meta-analysis to determine the optimal doses of IV ketamine and esketamine for treatment resistant depression. The post What Is the Optimal Dose of Ketamine for Treatment Resistant Depression? appeared first on Psychiatry Advisor.
  Meahjabeen Hoque
• Metacognitive Therapies Improve Schizophrenia Treatment Outcomes April 30, 2024
  Investigators conducted a meta-analysis to determine the efficacy of metacognitve therapies in treating proximal and distal measures of schizophrenia spectrum disorders. The post Metacognitive Therapies Improve Schizophrenia Treatment Outcomes appeared first on Psychiatry Advisor.
  Meahjabeen Hoque
• Seven in 10 Experiencing Homelessness Have a Mental Health Disorder April 30, 2024
  The majority of people experiencing homelessness have mental health disorders, according to a review published online. The post Seven in 10 Experiencing Homelessness Have a Mental Health Disorder appeared first on Psychiatry Advisor.
  Haymarket Media
• Lower Risk for MCI, Dementia Seen With Cognitively Stimulating Occupations April 30, 2024
  Individuals with a history of cognitively stimulating occupations from ages 30 to 65 years have lower risk for mild cognitive impairment (MCI) and dementia in later life. The post Lower Risk for MCI, Dementia Seen With Cognitively Stimulating Occupations appeared first on Psychiatry Advisor.
  Haymarket Media
• Could HSV Infection Double Dementia Risk Among Older Adults? April 30, 2024
  Researchers sought to assess the risk for AD and dementia among older adults with a history of HSV infection. The post Could HSV Infection Double Dementia Risk Among Older Adults? appeared first on Psychiatry Advisor.
  Addie
• Lixisenatide Decreases Motor Disability Progression in Early Parkinson Disease April 30, 2024
  In a phase 2, double-blind, randomized, placebo-controlled trial, researchers assessed the effect of lixisenatide on the progression of motor disability in patients with Parkinson disease. The post Lixisenatide Decreases Motor Disability Progression in Early Parkinson Disease appeared first on Psychiatry Advisor.
  Addie
• Is Atopic Dermatitis in Children Linked to Cognitive Impairment Symptoms? April 30, 2024
  In a cross-sectional study, researchers assessed the association of atopic dermatitis with cognitive impairment symptoms among children and whether this association varied with neurodevelopmental comorbidities. The post Is Atopic Dermatitis in Children Linked to Cognitive Impairment Symptoms? appeared first on Psychiatry Advisor.
  Addie
• Adrenal Insufficiency Relatively Common in Adults With HIV, Tuberculosis April 30, 2024
  Researchers evaluated the prevalent, clinical features, and predictors of adrenal insufficiency in adult patients infected with HIV or tuberculosis. The post Adrenal Insufficiency Relatively Common in Adults With HIV, Tuberculosis appeared first on Psychiatry Advisor.
  Aleta Terrill
• Psychotropic Medication Use in Pediatric Emergency Departments From 2013 to 2022 April 29, 2024
  Researchers conducted a retrospective study to evaluate psychotropic medication administration during pediatric emergency department encounters from 2013 to 2022. The post Psychotropic Medication Use in Pediatric Emergency Departments From 2013 to 2022 appeared first on Psychiatry Advisor.
  Meahjabeen Hoque
• Significantly Elevated Post Concussion Symptoms After Early Childhood Concussion April 29, 2024
  Researchers conducted a cohort study to characterize post concussion symptoms in the 3 months following early childhood concussion in children younger than 6 years. The post Significantly Elevated Post Concussion Symptoms After Early Childhood Concussion appeared first on Psychiatry Advisor.
  Meahjabeen Hoque